EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of Potential Prophylactic Medical Countermeasures Against Acute Radiation Syndrome (ARS)

Kia T Liermann-Wooldrik iD, Arpita Chatterjee, Elizabeth A Kosmacek, Molly S Myers, Oluwaseun Adebisi, Louise Monga-Wells, Liu Mei, Michelle P Takacs, Patrick H Dussault, Daniel R Draney, Robert Powers iD, James W Checco iD und 8 weitere

International Journal of Molecular Sciences · 25.04.2025 · 26 (9) · 4055

DOI: 10.3390/ijms26094055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.04.2025. Verfasst von Kia T Liermann-Wooldrik und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA. Hauptthemen laut MEDLINE: Acute Radiation Syndrome, Radiation-Protective Agents, Medical Countermeasures. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Strategic Research Institute, Nebraska Center for Integrated Biomolecular Communication.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute radiation syndrome (ARS) occurs when hematopoietic or gastrointestinal cells are damaged by radiation exposure causing DNA damage to the bone marrow and gastrointestinal epithelial stem cell populations. In these highly proliferative cell types, DNA damage inhibits stem cell repopulation. In humans and animals, this inability to regenerate stem cells is lethal. Within this manuscript, several compounds, Amifostine, Captopril, Ciprofloxacin, PrC-210, 5-AED (5-androstene-3β,17β-diol), and 5-AET (5-androstene-3β,7β,17B-triol), are assessed for their ability to protect against ARS in an in vitro and/or in vivo setting. ARS was accomplished by irradiating mouse bone marrow cells or rat intestinal epithelial (IEC-6) cells in vitro with 4–8 Gy and in vivo by exposing Mus musculus to 7.3 Gy of whole-body irradiation. The primary endpoints of this study include cellular viability, DNA damage via γ-H2AX, colony formation, and overall survival at 30-days post-irradiation. In addition to evaluating the radioprotective performance of each compound, this study establishes a distinct set of in vitro assays to predict the overall efficacy of potential radioprotectors in an in vivo model of ARS. Furthermore, these results highlight the need for FDA-approved medical intervention to protect against ARS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Radiation SyndromeRadiation-Protective AgentsMedical CountermeasuresAnimalsRatsMiceDNA DamageCell SurvivalBone Marrow CellsAmifostineMaleCell LineWhole-Body Irradiation

Stichwörter der Autor:innen

DNA damageacute radiation syndromeradioprotection

Substanzen

Radiation-Protective AgentsAmifostine

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • Department of Chemistry, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.
  • Nebraska Center for Integrated Biomolecular Communication, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.
  • Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • Center for Biomedical Informatics Research and Innovation, University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.

ORCID-Profile: Kia T Liermann-Wooldrik, Robert Powers, James W Checco, Chittibabu Guda, David B Berkowitz, Daryl J Murry, Rebecca E Oberley-Deegan

Förderung

  • NIGMS NIH HHS
  • National Strategic Research Institute
  • Nebraska Center for Integrated Biomolecular Communication
  • NCIBC Systems Biology Core

Zitieren

APA

Liermann-Wooldrik, K. T., Chatterjee, A., Kosmacek, E. A., Myers, M. S., Adebisi, O., Monga-Wells, L., Mei, L., Takacs, M. P., Dussault, P. H., Draney, D. R., Powers, R., Checco, J. W., Guda, C., Helikar, T., Berkowitz, D. B., Bayles, K. W., Epstein, A. H., Cary, L., Murry, D. J., & Oberley-Deegan, R. E. (2025). Identification of Potential Prophylactic Medical Countermeasures Against Acute Radiation Syndrome (ARS). International Journal of Molecular Sciences, 26(9), 4055. https://doi.org/10.3390/ijms26094055

Vancouver

Liermann-Wooldrik KT, Chatterjee A, Kosmacek EA, Myers MS, Adebisi O, Monga-Wells L, et al. Identification of Potential Prophylactic Medical Countermeasures Against Acute Radiation Syndrome (ARS). International Journal of Molecular Sciences. 2025;26(9):4055. doi:10.3390/ijms26094055

BibTeX
@article{LiermannWooldrik2025,
  author = {Liermann-Wooldrik, Kia T and Chatterjee, Arpita and Kosmacek, Elizabeth A and Myers, Molly S and Adebisi, Oluwaseun and Monga-Wells, Louise and Mei, Liu and Takacs, Michelle P and Dussault, Patrick H and Draney, Daniel R and Powers, Robert and Checco, James W and Guda, Chittibabu and Helikar, Tomáš and Berkowitz, David B and Bayles, Kenneth W and Epstein, Alan H and Cary, Lynnette and Murry, Daryl J and Oberley-Deegan, Rebecca E},
  title = {Identification of Potential Prophylactic Medical Countermeasures Against Acute Radiation Syndrome (ARS)},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {9},
  pages = {4055},
  doi = {10.3390/ijms26094055}
}
Kostenlos starten →